Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
EMA’s Medical Literature Monitoring: Shakedown or Shakeup
Posted on October 27th, 2015 by Julio dos Anjos in Pharmacovigilance
Although, quite a lot of existing flows have to change and new ones have to be implemented, there are, also, quite a lot of benefits, most of them for EMA, and some, not so obvious, for the MAH’s. Of these last ones, many are found by looking at the information, now made available by EMA, as an information professional in a pharmacovigilance context, as well as a pharmacovigilance analyst in an information rich environment.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Julio dos Anjos
Professional Services Consultant
- The Liabilities of Pharmacovigilance Activities
- What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?
- Shouldn’t pharmacovigilance be less painful?
- The Change Imperative: Finding the right balance as times change
- Building a balanced search formula for pharmacovigilance and literature monitoring